Johnson & Johnson (JNJ)
As of Oct 23, 2026, Kalshi and Polymarket have settled 70 word markets on Johnson & Johnson’s earnings calls since 2026, on 20 different words. Next call: Jan 26, 2027 (16 words listed).
| Word | Q4’24Jan '25 | Q1’25Apr '25 | Q2’25Jul '25 | Q3’25Oct '25 | Q4’25year ago | Q1’26Apr '26 | Q2’26Jul '26 | Q3’26last call | Trend | Last 8 | Scripted | All-time | Probability | Market |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Procedure | 6 times: Procedure, Q4’24 Jan '25, counts as said | 10 times: Procedure, Q1’25 Apr '25, counts as said | 2 times: Procedure, Q2’25 Jul '25, counts as said | 1 time: Procedure, Q3’25 Oct '25, counts as said | 3 times: Procedure, Q4’25 Jan '26, counts as said | 3 times: Procedure, Q1’26 Apr '26, counts as said | 11 times: Procedure, Q2’26 Jul '26, counts as said | 3 times: Procedure, Q3’26 Oct '26, counts as said | steady | 8/8100% | 8/8100% | 75/7896% | 93%n=4+tx from settlement history blended with transcripts | 86¢ Kalshi |
| Rybrevant | 9 times: Rybrevant, Q4’24 Jan '25, counts as said | 1 time: Rybrevant, Q1’25 Apr '25, counts as said | 8 times: Rybrevant, Q2’25 Jul '25, counts as said | 3 times: Rybrevant, Q3’25 Oct '25, counts as said | 3 times: Rybrevant, Q4’25 Jan '26, counts as said | 5 times: Rybrevant, Q1’26 Apr '26, counts as said | 5 times: Rybrevant, Q2’26 Jul '26, counts as said | 7 times: Rybrevant, Q3’26 Oct '26, counts as said | steady | 8/8100% | 8/8100% | 19/7824% | 93%n=4+tx from settlement history blended with transcripts | 88¢ Kalshi |
| Ottava | 2 times: Ottava, Q4’24 Jan '25, counts as said | 0 times: Ottava, Q1’25 Apr '25 | 5 times: Ottava, Q2’25 Jul '25, counts as said | 5 times: Ottava, Q3’25 Oct '25, counts as said | 3 times: Ottava, Q4’25 Jan '26, counts as said | 5 times: Ottava, Q1’26 Apr '26, counts as said | 6 times: Ottava, Q2’26 Jul '26, counts as said | 12 times: Ottava, Q3’26 Oct '26, counts as said | rising | 7/888% | 6/875% | 18/7823% | 93%n=4+tx from settlement history blended with transcripts | 82¢ Kalshi |
| Caplyta | 6 times: Caplyta, Q4’24 Jan '25, counts as said | 6 times: Caplyta, Q1’25 Apr '25, counts as said | 5 times: Caplyta, Q2’25 Jul '25, counts as said | 6 times: Caplyta, Q3’25 Oct '25, counts as said | 6 times: Caplyta, Q4’25 Jan '26, counts as said | 6 times: Caplyta, Q1’26 Apr '26, counts as said | 4 times: Caplyta, Q2’26 Jul '26, counts as said | 4 times: Caplyta, Q3’26 Oct '26, counts as said | steady | 8/8100% | 8/8100% | 8/7810% | 92%n=1+tx from settlement history blended with transcripts | 86¢ Kalshi |
| China | 7 times: China, Q4’24 Jan '25, counts as said | 5 times: China, Q1’25 Apr '25, counts as said | 1 time: China, Q2’25 Jul '25, counts as said | 1 time: China, Q3’25 Oct '25, counts as said | 3 times: China, Q4’25 Jan '26, counts as said | 2 times: China, Q1’26 Apr '26, counts as said | 3 times: China, Q2’26 Jul '26, counts as said | 2 times: China, Q3’26 Oct '26, counts as said | falling | 8/8100% | 7/888% | 68/7887% | 89%n=4+tx from settlement history blended with transcripts | 86¢ Kalshi |
| Tariff | 0 times: Tariff, Q4’24 Jan '25 | 17 times: Tariff, Q1’25 Apr '25, counts as said | 6 times: Tariff, Q2’25 Jul '25, counts as said | 2 times: Tariff, Q3’25 Oct '25, counts as said | 6 times: Tariff, Q4’25 Jan '26, counts as said | 2 times: Tariff, Q1’26 Apr '26, counts as said | 4 times: Tariff, Q2’26 Jul '26, counts as said | 2 times: Tariff, Q3’26 Oct '26, counts as said | falling | 7/888% | 7/888% | 9/7812% | 88%n=3+tx from settlement history blended with transcripts | 79¢ Kalshi |
| Tecvayli | 4 times: Tecvayli, Q4’24 Jan '25, counts as said | 1 time: Tecvayli, Q1’25 Apr '25, counts as said | 1 time: Tecvayli, Q2’25 Jul '25, counts as said | 0 times: Tecvayli, Q3’25 Oct '25 | 0 times: Tecvayli, Q4’25 Jan '26 | 4 times: Tecvayli, Q1’26 Apr '26, counts as said | 11 times: Tecvayli, Q2’26 Jul '26, counts as said | 3 times: Tecvayli, Q3’26 Oct '26, counts as said | rising | 6/875% | 5/862% | 15/7819% | 87%n=1+tx from settlement history blended with transcripts | 86¢ Kalshi |
| Litigation | 3 times: Litigation, Q4’24 Jan '25, counts as said | 2 times: Litigation, Q1’25 Apr '25, counts as said | 1 time: Litigation, Q2’25 Jul '25, counts as said | 2 times: Litigation, Q3’25 Oct '25, counts as said | 3 times: Litigation, Q4’25 Jan '26, counts as said | 0 times: Litigation, Q1’26 Apr '26 | 1 time: Litigation, Q2’26 Jul '26, counts as said | 4 times: Litigation, Q3’26 Oct '26, counts as said | steady | 7/888% | 7/888% | 72/7892% | 79%n=3+tx from settlement history blended with transcripts | 70¢ Kalshi |
| Firefly Bio | 0 times: Firefly Bio, Q4’24 Jan '25 | 0 times: Firefly Bio, Q1’25 Apr '25 | 0 times: Firefly Bio, Q2’25 Jul '25 | 0 times: Firefly Bio, Q3’25 Oct '25 | 0 times: Firefly Bio, Q4’25 Jan '26 | 0 times: Firefly Bio, Q1’26 Apr '26 | 3 times: Firefly Bio, Q2’26 Jul '26, counts as said | 9 times: Firefly Bio, Q3’26 Oct '26, counts as said | rising | 2/825% | 2/825% | 2/783% | 76%n=1+tx from settlement history blended with transcripts | 87¢ Kalshi |
| Darzalex Faspro | 0 times: Darzalex Faspro, Q4’24 Jan '25 | 0 times: Darzalex Faspro, Q1’25 Apr '25 | 0 times: Darzalex Faspro, Q2’25 Jul '25 | 0 times: Darzalex Faspro, Q3’25 Oct '25 | 0 times: Darzalex Faspro, Q4’25 Jan '26 | 2 times: Darzalex Faspro, Q1’26 Apr '26, counts as said | 1 time: Darzalex Faspro, Q2’26 Jul '26, counts as said | 1 time: Darzalex Faspro, Q3’26 Oct '26, counts as said | rising | 3/838% | 3/838% | 9/7812% | 63%n=4+tx from settlement history blended with transcripts | 69¢ Kalshi |
| Sail Biomedicines | 0 times: Sail Biomedicines, Q4’24 Jan '25 | 0 times: Sail Biomedicines, Q1’25 Apr '25 | 0 times: Sail Biomedicines, Q2’25 Jul '25 | 0 times: Sail Biomedicines, Q3’25 Oct '25 | 0 times: Sail Biomedicines, Q4’25 Jan '26 | 0 times: Sail Biomedicines, Q1’26 Apr '26 | 0 times: Sail Biomedicines, Q2’26 Jul '26 | 8 times: Sail Biomedicines, Q3’26 Oct '26, counts as said | rising | 1/812% | 1/812% | 1/781% | 60%transcripts from the transcript model | 56¢ Kalshi |
| Halda Therapeutics | 0 times: Halda Therapeutics, Q4’24 Jan '25 | 0 times: Halda Therapeutics, Q1’25 Apr '25 | 0 times: Halda Therapeutics, Q2’25 Jul '25 | 0 times: Halda Therapeutics, Q3’25 Oct '25 | 3 times: Halda Therapeutics, Q4’25 Jan '26, counts as said | 1 time: Halda Therapeutics, Q1’26 Apr '26, counts as said | 1 time: Halda Therapeutics, Q2’26 Jul '26, counts as said | 0 times: Halda Therapeutics, Q3’26 Oct '26 | rising | 3/838% | 2/825% | 3/784% | 50%n=4+tx from settlement history blended with transcripts | 24¢ Kalshi |
| AI / Artificial Intelligence | 0 times: AI / Artificial Intelligence, Q4’24 Jan '25 | 0 times: AI / Artificial Intelligence, Q1’25 Apr '25 | 0 times: AI / Artificial Intelligence, Q2’25 Jul '25 | 0 times: AI / Artificial Intelligence, Q3’25 Oct '25 | 0 times: AI / Artificial Intelligence, Q4’25 Jan '26 | 0 times: AI / Artificial Intelligence, Q1’26 Apr '26 | 1 time: AI / Artificial Intelligence, Q2’26 Jul '26, counts as said | 0 times: AI / Artificial Intelligence, Q3’26 Oct '26 | steady | 1/812% | 1/812% | 8/7810% | 23%n=3+tx from settlement history blended with transcripts | 34¢ Kalshi |
| Nipocalimab / Lupus | 2 times: Nipocalimab / Lupus, Q4’24 Jan '25, counts as said | 0 times: Nipocalimab / Lupus, Q1’25 Apr '25 | 0 times: Nipocalimab / Lupus, Q2’25 Jul '25 | 0 times: Nipocalimab / Lupus, Q3’25 Oct '25 | 1 time: Nipocalimab / Lupus, Q4’25 Jan '26, counts as said | 0 times: Nipocalimab / Lupus, Q1’26 Apr '26 | 0 times: Nipocalimab / Lupus, Q2’26 Jul '26 | 0 times: Nipocalimab / Lupus, Q3’26 Oct '26 | falling | 2/825% | 1/812% | 18/7823% | 22%n=4+tx from settlement history blended with transcripts | 21¢ Kalshi |
| Vaccine | 5 times: Vaccine, Q4’24 Jan '25, counts as said | 0 times: Vaccine, Q1’25 Apr '25 | 0 times: Vaccine, Q2’25 Jul '25 | 0 times: Vaccine, Q3’25 Oct '25 | 0 times: Vaccine, Q4’25 Jan '26 | 0 times: Vaccine, Q1’26 Apr '26 | 0 times: Vaccine, Q2’26 Jul '26 | 0 times: Vaccine, Q3’26 Oct '26 | falling | 1/812% | 1/812% | 36/7846% | 13%n=4+tx from settlement history blended with transcripts | 6¢ Kalshi |
| Gene Therapy | 0 times: Gene Therapy, Q4’24 Jan '25 | 0 times: Gene Therapy, Q1’25 Apr '25 | 0 times: Gene Therapy, Q2’25 Jul '25 | 0 times: Gene Therapy, Q3’25 Oct '25 | 0 times: Gene Therapy, Q4’25 Jan '26 | 0 times: Gene Therapy, Q1’26 Apr '26 | 0 times: Gene Therapy, Q2’26 Jul '26 | 0 times: Gene Therapy, Q3’26 Oct '26 | steady | 0/80% | 0/80% | 5/786% | 11%n=2+tx from settlement history blended with transcripts | 4¢ Kalshi |
- times said on that call
- counted as said (ring)
- no call
- probability next time, with n
- Select a word or a cell for its quotes
What the columns mean
- Last N
- of the appearances shown, how many counted as said
- Trend
- how the count moved over these calls
- Scripted
- calls of the last 8 where it was said in the prepared remarks
- All-time
- every call on file
- Probability
- the calibrated probability for the next listing; n is the settled observations behind it when it was computed, '+tx' adds the transcripts, 'new' means too little history
Market prices are mid quotes from Kalshi and Polymarket, shown for context, may be delayed by several minutes and are not a signal. Quotes as of Oct 20, 2026 15:46 UTC.
Every word
1–5 of 5, most settled first| Word | Q4’24Jan '25 | Q1’25Apr '25 | Q2’25Jul '25 | Q3’25Oct '25 | Q4’25Jan '26 | Q1’26Apr '26 | Q2’26Jul '26 | Q3’26last call | Trend | Last 8 | Scripted | All-time | Probability |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Administration | 0 times: Administration, Q4’24 Jan '25 | 6 times: Administration, Q1’25 Apr '25, counts as said | 2 times: Administration, Q2’25 Jul '25, counts as said | 3 times: Administration, Q3’25 Oct '25, counts as said | 1 time: Administration, Q4’25 Jan '26, counts as said | 0 times: Administration, Q1’26 Apr '26 | 0 times: Administration, Q2’26 Jul '26 | 0 times: Administration, Q3’26 Oct '26 | falling | 4/850% | 3/838% | 27/7835% | 26%n=4+tx from settlement history blended with transcripts |
| Europe | 7 times: Europe, Q4’24 Jan '25, counts as said | 2 times: Europe, Q1’25 Apr '25, counts as said | 1 time: Europe, Q2’25 Jul '25, counts as said | 2 times: Europe, Q3’25 Oct '25, counts as said | 1 time: Europe, Q4’25 Jan '26, counts as said | 3 times: Europe, Q1’26 Apr '26, counts as said | 0 times: Europe, Q2’26 Jul '26 | 3 times: Europe, Q3’26 Oct '26, counts as said | falling | 7/888% | 6/875% | 72/7892% | 73%n=3+tx from settlement history blended with transcripts |
| Trufill | 0 times: Trufill, Q4’24 Jan '25 | 0 times: Trufill, Q1’25 Apr '25 | 0 times: Trufill, Q2’25 Jul '25 | 0 times: Trufill, Q3’25 Oct '25 | 0 times: Trufill, Q4’25 Jan '26 | 0 times: Trufill, Q1’26 Apr '26 | 0 times: Trufill, Q2’26 Jul '26 | 0 times: Trufill, Q3’26 Oct '26 | steady | 0/80% | 0/80% | 3/784% | 11%n=3+tx from settlement history blended with transcripts |
| Carvykti | 10 times: Carvykti, Q4’24 Jan '25, counts as said | 5 times: Carvykti, Q1’25 Apr '25, counts as said | 4 times: Carvykti, Q2’25 Jul '25, counts as said | 6 times: Carvykti, Q3’25 Oct '25, counts as said | 6 times: Carvykti, Q4’25 Jan '26, counts as said | 2 times: Carvykti, Q1’26 Apr '26, counts as said | 2 times: Carvykti, Q2’26 Jul '26, counts as said | 4 times: Carvykti, Q3’26 Oct '26, counts as said | falling | 8/8100% | 8/8100% | 19/7824% | 90%n=2+tx from settlement history blended with transcripts |
| Halda Therapeutics / Haida Therapeutics | 0 times: Halda Therapeutics / Haida Therapeutics, Q4’24 Jan '25 | 0 times: Halda Therapeutics / Haida Therapeutics, Q1’25 Apr '25 | 0 times: Halda Therapeutics / Haida Therapeutics, Q2’25 Jul '25 | 0 times: Halda Therapeutics / Haida Therapeutics, Q3’25 Oct '25 | 3 times: Halda Therapeutics / Haida Therapeutics, Q4’25 Jan '26, counts as said | 1 time: Halda Therapeutics / Haida Therapeutics, Q1’26 Apr '26, counts as said | 1 time: Halda Therapeutics / Haida Therapeutics, Q2’26 Jul '26, counts as said | 0 times: Halda Therapeutics / Haida Therapeutics, Q3’26 Oct '26 | rising | 3/838% | 2/825% | 3/784% | 56%n=1+tx from settlement history blended with transcripts |
- times said on that call
- counted as said (ring)
- no call
- probability next time, with n
- Select a word or a cell for its quotes
What the columns mean
- Last N
- of the appearances shown, how many counted as said
- Trend
- how the count moved over these calls
- Scripted
- calls of the last 8 where it was said in the prepared remarks
- All-time
- every call on file
- Probability
- the calibrated probability for the next listing; n is the settled observations behind it when it was computed, '+tx' adds the transcripts, 'new' means too little history
Appearances and settled record
latest 12Our transcript counts matched how 70 of 70 settled words resolved (100.0%). How we check.
| Date | Appearance | Text | Words | Settled | Our count agreed |
|---|---|---|---|---|---|
| Oct 13, 2026 | Earnings call FY26 Q3 | Speaker-labelled transcript | 16 | 10 yes · 6 no | 16/16 (100%) |
| Jul 15, 2026 | Earnings call FY26 Q2 | Speaker-labelled transcript | 15 | 9 yes · 6 no | 15/15 (100%) |
| Apr 14, 2026 | Earnings call FY26 Q1 | Speaker-labelled transcript | 15 | 9 yes · 6 no | 15/15 (100%) |
| Jan 21, 2026 | Earnings call FY25 Q4 | Speaker-labelled transcript | 24 | 18 yes · 6 no | 24/24 (100%) |
| Oct 14, 2025 | Earnings call FY25 Q3 | Speaker-labelled transcript | 0 | – | – |
| Jul 16, 2025 | Earnings call FY25 Q2 | Speaker-labelled transcript | 0 | – | – |
| Apr 15, 2025 | Earnings call FY25 Q1 | Speaker-labelled transcript | 0 | – | – |
| Jan 22, 2025 | Earnings call FY24 Q4 | Speaker-labelled transcript | 0 | – | – |
| Oct 15, 2024 | Earnings call FY24 Q3 | Speaker-labelled transcript | 0 | – | – |
| Jul 17, 2024 | Earnings call FY24 Q2 | Speaker-labelled transcript | 0 | – | – |
| Apr 16, 2024 | Earnings call FY24 Q1 | Speaker-labelled transcript | 0 | – | – |
| Jan 23, 2024 | Earnings call FY23 Q4 | Speaker-labelled transcript | 0 | – | – |
Citeparrot.markets, “Johnson & Johnson (JNJ): earnings call word history”, as of Oct 23, 2026, https://parrot.markets/earnings/JNJ (CC BY 4.0)
Agents: this page as TSV at /api/v1/entity/johnson-and-johnson · words: /api/v1/history?entity=johnson-and-johnson · columnar JSON in #parrot-data · llms.txt · MCP